TN2014000417A1 - Heterobicyclic compounds as beta-lactamase inhibitors - Google Patents

Heterobicyclic compounds as beta-lactamase inhibitors

Info

Publication number
TN2014000417A1
TN2014000417A1 TN2014000417A TN2014000417A TN2014000417A1 TN 2014000417 A1 TN2014000417 A1 TN 2014000417A1 TN 2014000417 A TN2014000417 A TN 2014000417A TN 2014000417 A TN2014000417 A TN 2014000417A TN 2014000417 A1 TN2014000417 A1 TN 2014000417A1
Authority
TN
Tunisia
Prior art keywords
beta
lactamase inhibitors
compounds
heterobicyclic compounds
pharmaceutically acceptable
Prior art date
Application number
TN2014000417A
Other languages
English (en)
Inventor
Helen Mcguire
Shanta Bist
Neil Bifulco
Liang Zhao
Ve Wu
Hoan Huynh
Hui Xiong
Janelle Comita-Prevoir
T Daemian Dussaul
Brendan Chen
Thomas Durand-Reville
Satenig Guler
Bolin Geng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TN2014000417A1 publication Critical patent/TN2014000417A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2014000417A 2012-04-02 2014-10-02 Heterobicyclic compounds as beta-lactamase inhibitors TN2014000417A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618993P 2012-04-02 2012-04-02
PCT/GB2013/050869 WO2013150296A1 (fr) 2012-04-02 2013-04-02 Composés hétérobicycliques comme inhibiteurs de la bêta-lactamase

Publications (1)

Publication Number Publication Date
TN2014000417A1 true TN2014000417A1 (en) 2016-03-30

Family

ID=48083562

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2014000417A TN2014000417A1 (en) 2012-04-02 2014-10-02 Heterobicyclic compounds as beta-lactamase inhibitors

Country Status (41)

Country Link
US (2) US9309245B2 (fr)
EP (1) EP2834239B1 (fr)
JP (1) JP6122484B2 (fr)
KR (1) KR102042867B1 (fr)
CN (1) CN104364254B (fr)
AP (1) AP2014007980A0 (fr)
AR (1) AR090539A1 (fr)
AU (1) AU2013245399B2 (fr)
BR (1) BR112014024279B1 (fr)
CA (1) CA2866467C (fr)
CL (1) CL2014002589A1 (fr)
CO (1) CO7071137A2 (fr)
CR (1) CR20140428A (fr)
CY (1) CY1120269T1 (fr)
DK (1) DK2834239T3 (fr)
DO (1) DOP2014000212A (fr)
ES (1) ES2663416T3 (fr)
HR (1) HRP20180450T1 (fr)
HU (1) HUE036722T2 (fr)
IL (1) IL234660A (fr)
IN (1) IN2014MN01882A (fr)
LT (1) LT2834239T (fr)
MA (1) MA37383A1 (fr)
ME (1) ME03031B (fr)
MX (1) MX354627B (fr)
MY (1) MY176969A (fr)
NO (1) NO2935238T3 (fr)
NZ (1) NZ630259A (fr)
PE (1) PE20142403A1 (fr)
PH (1) PH12014502224B1 (fr)
PL (1) PL2834239T3 (fr)
PT (1) PT2834239T (fr)
RS (1) RS56966B1 (fr)
RU (1) RU2645678C2 (fr)
SG (1) SG11201405965RA (fr)
SI (1) SI2834239T1 (fr)
SM (1) SMT201800142T1 (fr)
TN (1) TN2014000417A1 (fr)
TW (1) TWI597281B (fr)
UY (1) UY34723A (fr)
WO (1) WO2013150296A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
BR112017010132B1 (pt) * 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
WO2016156344A1 (fr) 2015-03-31 2016-10-06 Mutabilis Composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
EP3075733A1 (fr) * 2015-03-31 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
WO2016156348A1 (fr) 2015-03-31 2016-10-06 Mutabilis Nouveaux composés hétérocycliques et utilisation de ceux-ci pour prévenir ou traiter des infections bactériennes
EP3075381A1 (fr) * 2015-04-03 2016-10-05 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
RU2714197C2 (ru) * 2015-04-03 2020-02-13 Мутабилис Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3091018A1 (fr) * 2015-05-07 2016-11-09 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
CA3000087A1 (fr) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions et methodes pour inhiber la beta-lactamase
EP3184529A1 (fr) * 2015-12-23 2017-06-28 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
WO2017203266A1 (fr) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Polythérapie pour le traitement d'infections bactériennes résistantes
CA3036557A1 (fr) * 2016-09-16 2018-03-22 Entasis Therapeutics Limited Composes inhibiteurs de beta-lactamase
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3301094A1 (fr) * 2016-09-30 2018-04-04 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
EP3300736B1 (fr) 2016-09-30 2021-05-05 Mutabilis Composition comprenant un composé antibiotique et un composé hétérocyclique et leur utilisation pour prévenir ou traiter des infections bactériennes
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
PL3630111T3 (pl) * 2017-05-08 2022-05-23 Entasis Therapeutics, Inc. Związki i sposoby leczenia zakażeń bakteryjnych
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11497731B2 (en) 2018-05-14 2022-11-15 National University Corporation Tokai National Higher Education And Research System β-lactamase inhibitor
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3608318A1 (fr) * 2018-08-09 2020-02-12 Antabio SAS Derives de diaazabicyclooctanone comme antibiotiques
KR102790878B1 (ko) * 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논
RU2739761C2 (ru) * 2018-09-27 2020-12-28 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения n-алкил-n-{ [3-алкил-3,8-диазабицикло[3.2.1]окта-1(7),5-диен-8-ил]метил} аминов и их применение в качестве средств с антимикробной активностью
CN111196808B (zh) * 2018-11-16 2022-10-18 南京圣和药业股份有限公司 二氮杂双环类化合物及其应用
CN110615790A (zh) * 2019-10-24 2019-12-27 北京融英医药科技有限公司 一种利格列汀制备工艺的改进方法
US20220194791A1 (en) * 2020-12-22 2022-06-23 Tokyo Ohka Kogyo Co., Ltd. Method for producing aqueous solution of purified orthoperiodic acid, method for producing semiconductor device, and aqueous solution of orthoperiodic acid
EP4281042A1 (fr) * 2021-01-20 2023-11-29 Entasis Therapeutics Limited Compositions d'antibiotiques à dose fixe
CN113979981B (zh) * 2021-10-22 2023-04-07 天津医科大学 一种巯基响应型脱碱基位点捕获试剂及应用
WO2023206580A1 (fr) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Formes cristallines de durlobactam
CN118271319B (zh) * 2022-12-30 2025-02-28 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
WO2024227071A1 (fr) 2023-04-26 2024-10-31 Entasis Therapeutics Limited Synthèse de durlobactam
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法
CN119998293A (zh) 2023-08-08 2025-05-13 成都四面体药物研究有限公司 一种含脲三环的β-内酰胺酶抑制剂、其制备方法及其用途
WO2025106662A1 (fr) 2023-11-15 2025-05-22 Entasis Therapeutics, Inc. Préparation d'intermédiaires d'acide boronique utiles dans la préparation de composés pour le traitement d'infections bactériennes
WO2025239896A1 (fr) 2024-05-16 2025-11-20 Entasis Therapeutics, Inc. Traitement de pneumonie bactérienne nosocomiale et pneumonie bactérienne acquise sous ventilation mécanique provoquée par des isolats sensibles de complexe acinetobacter baumannii-calcoaceticus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ274915A (en) * 1993-12-29 1997-11-24 Pfizer N-(hetero)aryl methyl diazabicycloalkane derivatives
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
MY162532A (en) 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (fr) * 2008-06-19 2017-12-27 Astra Zeneca Holding France Utilisation de (1r, 2s, 5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy) -, sel monosodique en tant que réactif de diagnostic pour la détection de sérines bêta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
KR101512738B1 (ko) 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
KR20140144254A (ko) 2012-03-30 2014-12-18 큐비스트 파마슈티컬즈 인코포레이티드 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 β-락타마제 억제제
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2014011825A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
CA2881169C (fr) 2012-08-25 2020-06-16 Wockhardt Limited Derives de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bacteriennes
WO2014141132A1 (fr) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. Nouveaux composés hétérocycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase

Also Published As

Publication number Publication date
JP6122484B2 (ja) 2017-04-26
BR112014024279B1 (pt) 2021-09-08
ES2663416T3 (es) 2018-04-12
BR112014024279A2 (fr) 2017-06-20
EP2834239A1 (fr) 2015-02-11
ME03031B (fr) 2018-10-20
SI2834239T1 (en) 2018-05-31
CA2866467A1 (fr) 2013-10-10
AR090539A1 (es) 2014-11-19
IL234660A (en) 2017-08-31
NZ630259A (en) 2016-06-24
LT2834239T (lt) 2018-03-26
KR20140140625A (ko) 2014-12-09
AU2013245399A1 (en) 2014-10-02
CL2014002589A1 (es) 2015-01-30
HK1207071A1 (en) 2016-01-22
CY1120269T1 (el) 2019-07-10
CO7071137A2 (es) 2014-09-30
MX2014011351A (es) 2014-12-05
AP2014007980A0 (en) 2014-10-31
PT2834239T (pt) 2018-03-23
AU2013245399B2 (en) 2016-04-21
MA37383A1 (fr) 2016-06-30
RS56966B1 (sr) 2018-05-31
UY34723A (es) 2015-07-31
PL2834239T3 (pl) 2018-06-29
DOP2014000212A (es) 2014-10-31
TWI597281B (zh) 2017-09-01
BR112014024279A8 (pt) 2018-04-03
RU2645678C2 (ru) 2018-02-27
US20160175290A1 (en) 2016-06-23
IN2014MN01882A (fr) 2015-07-10
DK2834239T3 (en) 2018-03-26
TW201345907A (zh) 2013-11-16
JP2015512440A (ja) 2015-04-27
PH12014502224B1 (en) 2017-11-08
SG11201405965RA (en) 2014-10-30
SMT201800142T1 (it) 2018-05-02
CN104364254A (zh) 2015-02-18
CR20140428A (es) 2015-01-12
KR102042867B1 (ko) 2019-11-08
US9623014B2 (en) 2017-04-18
RU2014141579A (ru) 2016-05-27
MX354627B (es) 2018-03-14
US9309245B2 (en) 2016-04-12
HUE036722T2 (hu) 2018-07-30
CA2866467C (fr) 2020-03-24
HRP20180450T1 (hr) 2018-06-01
US20150073011A1 (en) 2015-03-12
EP2834239B1 (fr) 2017-12-27
CN104364254B (zh) 2017-02-22
NO2935238T3 (fr) 2018-05-26
MY176969A (en) 2020-08-28
WO2013150296A1 (fr) 2013-10-10
PH12014502224A1 (en) 2015-01-12
PE20142403A1 (es) 2015-01-23

Similar Documents

Publication Publication Date Title
MX354627B (es) Compuestos heterociclicos como inhibidores de beta-lactamasas.
PH12019500558A1 (en) Beta-lactamase inhibitor compounds
PH12017502418A1 (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
EA201500544A1 (ru) НОВЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ АГЕНТОВ И ИНГИБИТОРОВ β-ЛАКТАМАЗ
WO2013122888A3 (fr) Méthodes de traitement d'infections bactériennes
TN2014000297A1 (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
BR112017010132A2 (pt) terapia combinada para tratamento de infecções bacterianas resistentes
WO2014022382A3 (fr) Inhibiteurs de protéine kinase antibactérienne
EP2590978A4 (fr) Agents antibactériens de carbapénem avec activité anti-gram négatif
MX355561B (es) Proceso para hacer inhibidores de girasa y topoisomerasa iv.
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
WO2013106756A3 (fr) Agents antimicrobiens
GB201117051D0 (en) Carbonic anhydrase inhibitors
IN2015DN03869A (fr)
EA201990738A1 (ru) Соединения-ингибиторы бета-лактамаз
GEP20186874B (en) Hydrochloride salts of an antibiotic compound
EA202190444A1 (ru) Диазабициклооктаноны в качестве ингибиторов сериновых бета-лактамаз